Kieszkowska Rutkowska Kolasinski Kancelaria Prawna sp. j.
We only have limited information for this firm. Consider the following firms which have provided more information:
Hailed as being ‘absolutely unique in the Polish market’, Kieszkowska Rutkowska Kolasinski Kancelaria Prawna sp. j. acts for a diverse client base of healthcare providers, medical device producers, and biotech companies in the full range of sector-specific matters. Practice co-head Paulina Kieszkowska-Knapik advises a number of industry associations and pharmacies on distribution structures, co-operations between pharmacies and online platforms, and the reimbursement of orphan drugs and medical products. Fellow co-head Ewa Rutkowska assists both Polish and global corporates across the pharmaceutical and medical devices industries with public consultations, as well as acting in product liability disputes. Michał Chodorek is noted for his expansive expertise in drug development and manufacturing projects, in addition to regulations governing the division of IP rights to discoveries. Michał Tracz‘s primary areas of focus are food supplements and biocidal products, and he was promoted to partner in February 2023. Bartłomiej Sasin is another active team member.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The law firm is characterised by extensive knowledge. They answer quickly and thoroughly. They are very meticulous and at the same time are businesslike. They provide great support on a daily basis, as well as in emergency situations.’
‘I would like to highlight three people, Katarzyna Kęska, Justyna Nowak, and Monika Kupis, for their exceptional knowledge and support. These are three exceptional lawyers. They have a very insightful approach, are able to present various ideas, indicate individual risks and mitigate these risks.’
Abbreviated data is displayed for this firm.
Key clients
- Celon Pharma S.A.
- Mabion S.A.
Abbreviated data is displayed for this firm.
Work highlights
- Advised MABION S.A. on a transaction which involved the conclusion of an agreement with Novavax Inc., under which the client will participate in the production of the Covid-19 Novavax vaccine.
- Advising several companies developing AI/ML medical devices on issues relating to their design, development, qualification, and validation.
Abbreviated data is displayed for this firm.